

Special Issue

New Advances in Treatment of Sepsis

Message from the Guest Editor

Sepsis is now defined as an organ dysfunction caused by an overwhelming and life-threatening host response to infection. Excessive inflammatory response in sepsis subsequently leads to multiple organ dysfunction syndrome due to vascular endothelial dysfunction, coagulation disorders, alterations in cell function, and dysregulated cardiovascular responses. Despite the progress made in medical management over the past few decades, sepsis remains an important global health problem, with approximately 11 million sepsis-related deaths reported in 2017. Although various strategies to control sepsis-induced inflammation and organ dysfunction have been evaluated over the past several decades, there is still no proven therapeutic intervention benefitting survival. Therefore, updating knowledge on the pathophysiology of sepsis is a vitally important issue to construct a novel therapeutic strategy of sepsis. In this Special Issue of the *Journal of Personalized Medicine*, we will discuss the etiology, pathophysiology, clinical manifestations, diagnostic, and optimal management to treat critically ill patients with sepsis.

Guest Editor

Dr. Yutaka Umemura

Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan

Deadline for manuscript submissions

closed (27 May 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/84402

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://jpm.mdpi.com)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).